Quantcast
Home > Quotes > HJLIW

Hancock Jaffe Laboratories, Inc. Warrants (HJLIW) Quote & Summary Data

HJLIW 
$0.3999
*  
unch
unch
Get HJLIW Alerts
*Delayed - data as of Feb. 22, 2019 15:42 ET  -  Find a broker to begin trading HJLIW now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    HJLIW Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 0.30 / $ 0.398
1 Year Target
Today's High / Low
N/A / N/A
Share Volume
0
50 Day Avg. Daily Volume
N/A
Previous Close
$ 0.3999
52 Week High / Low
$ 1.7999 / $ 0.2115
Market Cap
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
0
50 Day Avg. Daily Volume:
N/A

Trading Range

The current last sale of $0.3999 is 89.08% Higher than the 52 week low.

Intraday Last 52 Weeks
High: N/A $ 1.7999
 Low: N/A $ 0.2115

Company Description (as filed with the SEC)

We are a development stage medical device company developing biologic-based solutions that are designed to be life-enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and ESRD. Each product candidate we are developing is designed to allow vascular and cardiothoracic surgeons to achieve effectiveness while improving current procedures and healthcare for a variety of patients. We are in the process of developing and obtaining FDA approval for the following three product candidates: the Bioprosthetic Heart Valve, which we refer to as BHV, the Bioprosthetic Coronary Artery Bypass Graft, which we refer to as CoreoGraft, and the Bioprosthetic Venous Valve, which we refer to as the VenoValve. We have previously manufactured, developed and obtained FDA pre-market approval for the ProCol Vascular Bioprosthesis, a product for hemodialysis vascular access in patients with ESRD, which we sold to LMAT in March 2016.  ... More ...  

Nasdaq Official Price

Open Price:
N/A
Open Date:
N/A
Close Price:
N/A
Close Date:
N/A

Research Brokers before you trade

Want to trade FX?

Analyst Info